Expert for Cell Culture & Regenerative Medicine, Miltenyi Biotec
BIOGRAPHY
Speakers
-
Dr. Rafal Krol
Principal Investigator, Research and Development Center, CiRA FoundationBIOGRAPHY
Event Date & Time
Date: September 09, 2021
Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST), 11:00pm (CST)
Abstract
Human pluripotent stem cells (PSCs) hold great potentials in regenerative therapies. In this webinar, Chao will first present the closed and automated CliniMACS Prodigy® Adherent Cell Culture process and the established PSC expansion and differentiation workflows. Afterwards, Rafal will shortly introduce the CiRA Foundation, an offshoot of the Center for iPS Cell Research and Application (CiRA), Kyoto University that assumed control of CiRA's management of induced pluripotent stem cells (iPS cells) and acts as a bridge for the transfer of iPS cell technology to the industry. Then, he will discuss the progress of protocol optimization for large-scale expansion of clinical grade iPS cells with the CliniMACS Prodigy Adherent Cell Culture process.
There will be time for questions and discussion after the presentation.
Learning Objectives
- How to build customized PSC expansion and differentiation processes in an automated, scalable, and closed manufacturing system.
- How to effectively transition from manual iPS cell expansion protocols to automated and functionally closed cell manufacturing.
- What modifications of the manual iPS cell expansion protocol are required for the CliniMACS Prodigy Adherent Cell Culture process.
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.
You May Also Like
DEC 10, 2024 | 9:00 AM
To-date, proteomic analysis has been severely limited in scale and resolution. Analyzing protein samples using an intact, single-molecule approach holds th...
OCT 02, 2024 | 7:30 AM
De novo gene synthesis and protein expression are established technologies that can give access to nearly any target DNA or protein sequence, allowing for engineering of biologics. In this p...
Loading Comments...